Create an Account
  1. Home
  2. Upcoming Events

Stemming the Tide on MASLD/MASH: It Starts on the Frontlines in Endocrinology and Primary Care Clinics 

Take time on Global Fatty Liver Day to learn more about cardiometabolic risk factors and improve your care of patients with MASLD/MASH. 

Live Broadcast
1.00 available credits
Information
June 12, 2025
12:00 PM - 01:00 PM EDT
Virtual
Healthcare Image

This broadcast will start in exactly:

  • 0

    Day(s)

  • 0

    Hour(s)

  • 0

    Minute(s)

  • 0

    Second(s)

ENROLL
Details
Presenters

  • Overview

    The epidemic of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) is fully upon the US healthcare system, and it's projected to get worse. The prevalence of MASLD in the US is expected to increase from 33.7% in 2020 to 41.4% in 2050, which translates to approximately 122 million adults being affected. Our broadcast on Global Fatty Liver Day will provide practical and engaging discussions to help endocrinologists and primary care providers better understand the use of noninvasive tests and biomarkers for timely screening and primary risk assessment, timely treatment and management of cardiometabolic risk, and timely assignment to the appropriate level of care for patients with MASLD/MASH.

     

  • Agenda

    Time                                  Topic

    12:00-12:05                     Welcome and Introductions

                                              Meena Bansal, MD

    12:05-12:20                     WHY Are We Here? 

                                              Nicholas Pennings, DO

    12:20-12:35                     WHAT Can PCPs and Endocrinologists Do About It?

                                              Fernando Bril, MD

    12:35-12:50                      HOW Do We Manage Patients With Significant Fibrosis?

                                              Meena Bansal, MD

    12:50-1:00                       Live Q&A

                                              All Faculty

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Chair:
    Meena B. Bansal, MD, FAASLD 
    Professor of Medicine 
    System Chief, Division of Liver Diseases 
    Icahn School of Medicine at Mount Sinai 
    New York, NY

    Dr. Bansal has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months: 
    Advisor/Consultant: Boston Pharma, Fibronostics, GSK, Intercept, Madrigal, Merck, Novo Nordisk, Pfizer, The Kinetix Group 
    Contracted Researcher: HistoIndex, Pfizer, Siemens, The Kinetix Group

    Faculty:
    Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP  
    Director, Clinical Health Services
    Chair and Professor of Family Medicine
    Campbell University Health Center  
    Buies Creek, NC  

    Dr. Nicholas Pennings has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Advisor/Consultant: Abbott, Novo Nordisk
    Other: Medifast  

    Fernando Bril, MD
    Assistant Professor, Department of Medicine
    Division of Endocrinology, Diabetes
    The University of Alabama at Birmingham
    Birmingham, AL

    Dr. Fernando Bril has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Advisor/Consultant: Boehringer Ingelheim, Novo Nordisk  

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose.
    • Rosanne Strauss, PharmD, has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 

  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Perform a health assessment to identify metabolic dysfunction-associated liver disease (MASLD) in a patient with documented metabolic risk factors for MASLD/metabolic dysfunction-associated steatohepatitis (MASH)
    • Use noninvasive tests (NITs) and biomarkers available in endocrinology and primary care practice settings to stratify risk of advanced hepatic fibrosis
    • Recommend evidence-based, guideline-concordant treatment for a patient with MASLD based on results of NITs and/or biomarkers
    • Interpret results of data from phase 3 clinical trials on emerging glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for lowering cardiometabolic risk and treating MASH
    • Interpret results of NITs to determine when a patient with MASLD/MASH should be referred for specialty care

     

  • Target Audience

    This activity has been designed to meet the educational needs of primary care physicians and endocrinologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with MASLD/MASH. 

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) t hrough the joint providership of Global Learning Collaborative (GLC) and Global Liver Institute. Global Learning Collaborative is accredited by the ACCME to provide continuing medical education for physicians. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).

    The Universal Activity Number for this program is JA0006235-9999-25-067-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net)

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.

     

  • Provider(s)/Educational Partner(s)


    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant Boehringer Ingelheim Pharmaceuticals, Inc. and Novo Nordisk, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 

    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

Details
Presenters

  • Overview

    The epidemic of metabolic dysfunction-associated liver disease (MASLD) and metabolic dysfunction-associated steatohepatitis (MASH) is fully upon the US healthcare system, and it's projected to get worse. The prevalence of MASLD in the US is expected to increase from 33.7% in 2020 to 41.4% in 2050, which translates to approximately 122 million adults being affected. Our broadcast on Global Fatty Liver Day will provide practical and engaging discussions to help endocrinologists and primary care providers better understand the use of noninvasive tests and biomarkers for timely screening and primary risk assessment, timely treatment and management of cardiometabolic risk, and timely assignment to the appropriate level of care for patients with MASLD/MASH.

     

  • Agenda

    Time                                  Topic

    12:00-12:05                     Welcome and Introductions

                                              Meena Bansal, MD

    12:05-12:20                     WHY Are We Here? 

                                              Nicholas Pennings, DO

    12:20-12:35                     WHAT Can PCPs and Endocrinologists Do About It?

                                              Fernando Bril, MD

    12:35-12:50                      HOW Do We Manage Patients With Significant Fibrosis?

                                              Meena Bansal, MD

    12:50-1:00                       Live Q&A

                                              All Faculty

  • Disclosure of Conflicts of Interest

    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs.

    Chair:
    Meena B. Bansal, MD, FAASLD 
    Professor of Medicine 
    System Chief, Division of Liver Diseases 
    Icahn School of Medicine at Mount Sinai 
    New York, NY

    Dr. Bansal has reported the following relevant financial relationships with ineligible companies of any amount during the past 24 months: 
    Advisor/Consultant: Boston Pharma, Fibronostics, GSK, Intercept, Madrigal, Merck, Novo Nordisk, Pfizer, The Kinetix Group 
    Contracted Researcher: HistoIndex, Pfizer, Siemens, The Kinetix Group

    Faculty:
    Nicholas Pennings, DO, DABOM, MFOMA, FACOFP, FAAFP  
    Director, Clinical Health Services
    Chair and Professor of Family Medicine
    Campbell University Health Center  
    Buies Creek, NC  

    Dr. Nicholas Pennings has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Advisor/Consultant: Abbott, Novo Nordisk
    Other: Medifast  

    Fernando Bril, MD
    Assistant Professor, Department of Medicine
    Division of Endocrinology, Diabetes
    The University of Alabama at Birmingham
    Birmingham, AL

    Dr. Fernando Bril has reported the following relevant financial relationships or relationships with ineligible companies of any amount during the past 24 months:  
    Advisor/Consultant: Boehringer Ingelheim, Novo Nordisk  

    Reviewers/Content Planners/Authors: 

    • Cindy Davidson has no relevant relationships to disclose.
    • Rosanne Strauss, PharmD, has no relevant relationships to disclose.
    • Brian P. McDonough, MD, FAAFP, has no relevant relationships to disclose. 

  • Learning Objectives

    Upon completion of this activity, learners should be better able to:

    • Perform a health assessment to identify metabolic dysfunction-associated liver disease (MASLD) in a patient with documented metabolic risk factors for MASLD/metabolic dysfunction-associated steatohepatitis (MASH)
    • Use noninvasive tests (NITs) and biomarkers available in endocrinology and primary care practice settings to stratify risk of advanced hepatic fibrosis
    • Recommend evidence-based, guideline-concordant treatment for a patient with MASLD based on results of NITs and/or biomarkers
    • Interpret results of data from phase 3 clinical trials on emerging glucagon-like peptide-1 receptor agonists (GLP-1 RAs) for lowering cardiometabolic risk and treating MASH
    • Interpret results of NITs to determine when a patient with MASLD/MASH should be referred for specialty care

     

  • Target Audience

    This activity has been designed to meet the educational needs of primary care physicians and endocrinologists as well as all other physicians, physician assistants, nurse practitioners, nurses, pharmacists, and healthcare providers involved in managing patients with MASLD/MASH. 

  • Accreditation and Credit Designation Statements

    This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) t hrough the joint providership of Global Learning Collaborative (GLC) and Global Liver Institute. Global Learning Collaborative is accredited by the ACCME to provide continuing medical education for physicians. 

    Global Learning Collaborative (GLC) designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 nursing contact hour(s). Nurses should claim only the credit commensurate with the extent of their participation in the activity.

    Global Learning Collaborative (GLC) designates this activity for 1.0 contact hour(s)/0.1 CEUs of pharmacy contact hour(s).

    The Universal Activity Number for this program is JA0006235-9999-25-067-L01-P. This learning activity is application-based. Your CE credits will be electronically submitted to the NABP upon successful completion of the activity. Pharmacists with questions can contact NABP customer service (custserv@nabp.net)

    Global Learning Collaborative (GLC) has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit(s) for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 CME credit(s). PAs should claim only the credit commensurate with the extent of their participation in the activity.

     

  • Provider(s)/Educational Partner(s)


    Our ultimate goal is to improve the care being delivered to patients, and our high-quality, evidence-based CME initiatives reflect our dedication to the creation and execution of excellence and are the product of shared research, knowledge, and clinical practice skills across the healthcare continuum.

  • Commercial Support

    This activity is supported by an independent educational grant Boehringer Ingelheim Pharmaceuticals, Inc. and Novo Nordisk, Inc. 

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Medtelligence. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to access a site outside of Medtelligence you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site. 

    Reproduction Prohibited 

    Reproduction of this material is not permitted without written permission from the copyright owner. 

  • System Requirements

    • Supported Browsers (2 most recent versions):
      • Google Chrome for Windows, Mac OS, iOS, and Android
      • Apple Safari for Mac OS and iOS
      • Mozilla Firefox for Windows, Mac OS, iOS, and Android
      • Microsoft Edge for Windows
    • Recommended Internet Speed: 5Mbps+

LIVE ON REACHMD RADIOBack to live radio
ReachMD Radio

Loading...

00:00
00:00
    Register

    We're glad to see you're enjoying Medtelligence…
    but how about a more personalized experience?

    Register for free